Related Experiment Videos
MYC and AMPK-Save Energy or Die!
Heidi M Haikala1, Johanna M Anttila1, Juha Klefström1
1Research Programs Unit/Translational Cancer Biology, Cancer Cell Circuitry Laboratory, Institute of Biomedicine, University of HelsinkiHelsinki, Finland.
Frontiers in Cell and Developmental Biology
|April 27, 2017
Summary
The MYC protein drives cancer cell growth by boosting metabolism, leading to energy depletion and activating AMPK. This sustained stress forces AMPK into a pro-death role, offering potential cancer therapy targets.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Background:
- The MYC oncogene promotes uncontrolled cell proliferation by reprogramming cellular metabolism to support biomass synthesis.
- MYC hijacks the citric acid cycle for biosynthesis, depleting ATP and activating AMP-activated protein kinase (AMPK).
- Unlike normal cells, MYC-driven cancer cells cannot exit the cell cycle to restore energy levels, leading to sustained metabolic stress.
Purpose of the Study:
- To review the roles of MYC and AMPK in cancer metabolism.
- To explore the interplay between anabolic MYC and catabolic AMPK pathways.
- To identify potential therapeutic vulnerabilities arising from their combined activity.
Main Methods:
- Literature review of MYC's metabolic reprogramming.
- Analysis of AMPK activation under MYC-driven metabolic stress.
- Discussion of synthetic lethal interactions between MYC and AMPK pathways.
Main Results:
- MYC promotes anabolic processes (lipids, nucleotides, proteins) at the expense of ATP production.
- Sustained metabolic stress and cell cycle activation induce a switch in AMPK from energy sensing to apoptosis induction.
- The combined activity of MYC and AMPK creates a metabolic vulnerability in cancer cells.
Conclusions:
- MYC's metabolic reprogramming and subsequent AMPK activation contribute to cancer progression.
- The shift of AMPK to a pro-apoptotic function under MYC influence presents a novel therapeutic angle.
- Targeting the synthetic lethal vulnerabilities arising from concurrent MYC and AMPK pathway activity may offer new cancer treatment strategies.